) The Marshfield Community Clinical Oncology Program (CCOP) has been, participating with the National Cancer Institute (NCI) since the inception of CCOP in 1983. The goal was to bring in s t ate-of-the-art cancer therapy in community-based institutions. The Marshfield CCOP program is administered under the auspices of Marshfield Medical Research and Education Foundation (MMREF), a Division of Marshfield Clinic. Very large numbers of cancer patients are receiving primary, secondary, and tertiary care delivered by over 450 multi-specialty physicians within the Marshfield Clinic group practice system. It is the goal of the Marshfield CCOP to provide state-of-the-art cancer treatment to these patients through various NCI approved protocols by collaborating with the Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), MD Anderson Cancer Center (MDACC) CCOP research base, Children's Cancer Group (CCG) research base, and the University of Rochester Cancer Center (URCC) cancer control research base. These protocol studies consisting of state-of-the-art cancer treatment trials and prevention and control research are aimed at improving quality of life and reducing cancer incidence and morbidity and mortality of cancer patients. NCI directed program, namely the audit process, institutional review board program, and investigational drug program, will be maintained. Office for Protection from Research Risks (OPRR) guidelines will be followed. One hundred ten to 120 credits in clinical trials and 70-75 cancer prevention and control credits will be the annual goal in the Marshfield CCOP. Marshfield CCOP personnel will continue to attend research-base organizational and educational meetings, and participate in their committee and scientific activities as needed. Quarterly and annual accrual reports and institutional changes will be reported periodically to NCI. Protocol participation helps to improve the quality in surgical approaches, pathology interpretations, and laboratory studies in the community setting. Cancer prevention and control research will involve various other subspecialties in medicine. Cancer prevention, early detection, symptom control, rehabilitation, and quality of life measurement will improve longevity and functional status of cancer patients. Marshfield CCOP will continue to maintain a superior and productive CCOP program during the next several years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035412-16
Application #
2894584
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J3))
Program Officer
Parnes, Howard L
Project Start
1983-09-01
Project End
2003-05-31
Budget Start
1999-06-25
Budget End
2000-05-31
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Marshfield Clinic Research Foundation
Department
Type
DUNS #
074776030
City
Marshfield
State
WI
Country
United States
Zip Code
54449
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Cleeland, Charles S; Zhao, Fengmin; Chang, Victor T et al. (2013) The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119:4333-40
Rowe, J M; Andersen, J W; Mazza, J J et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-62
Kay, N E; Oken, M M; Mazza, J J et al. (1988) Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2. Nouv Rev Fr Hematol 30:475-8
Krause, D; Lesiak, K; Imai, J et al. (1986) Activation of 2-5A-dependent RNase by analogs of 2-5A (5'-O-triphosphoryladenylyl(2'----5')adenylyl(2'----5')adenosine ) using 2',5'-tetraadenylate (core)-cellulose. J Biol Chem 261:6836-9